Modeling the clinical and economic implications of obesity using microsimulation

Journal of Medical Economics

Volumn 18, Issue 11, 2015, Pages 886-897

  Su, W ^a   Huang, J ^b   Chen, F ^b   Iacobucci, W ^b   Mocarski, M ^b   Dall, T M ^a   Perreault, L ^c  

^a FEKETE ASSOCIATES INC   (United States)

^b NOVO NORDISK INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Burden of illness; Economic analysis; Microsimulation; Obesity

Indexed keywords

ABSENTEEISM; ADULT; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER INCIDENCE; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; ECONOMIC ASPECT; EMPLOYMENT; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; GALLBLADDER CANCER; GALLBLADDER DISEASE; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HUMAN; INCIDENCE; INCOME; ISCHEMIC HEART DISEASE; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MICROSIMULATION; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHODGKIN LYMPHOMA; OBESITY; OSTEOARTHRITIS; OVARY CANCER; PANCREAS CANCER; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SIMULATION; SLEEP DISORDERED BREATHING; STOMACH CANCER; THYROID CANCER; AGED; AGING; BODY MASS; COMPLICATION; COST; COST OF ILLNESS; DEPRESSIVE DISORDER, MAJOR; ECONOMICS; HEALTH SERVICE; MARKOV CHAIN; SLEEP APNEA SYNDROMES; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ABSENTEEISM; ADULT; AGED; AGING; BODY MASS INDEX; BODY WEIGHT; COMORBIDITY; COST OF ILLNESS; COSTS AND COST ANALYSIS; DEPRESSIVE DISORDER, MAJOR; EMPLOYMENT; FEMALE; HEALTH SERVICES; HUMANS; INCOME; MALE; MARKOV CHAINS; MIDDLE AGED; OBESITY; QUALITY OF LIFE; SLEEP APNEA SYNDROMES; SOCIOECONOMIC FACTORS;

EID: 84945492260     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1058805     Document Type: Article

References (80)

1. Levi J, Segal L, Thomas K, et al. F as in Fat: how obesity threatens America's future, 2013. http://healthyamericans.org/assets/files/TFAH2013 FasInFatReportFinal%209.9.pdf. Accessed June 18, 2015
2. Center for Disease Control and Prevention. Adult obesity facts. Atlanta, GA, 2014. http://www.cdc.gov/obesity/data/adult.html. Accessed November 30, 2014
3. Finkelstein E, Trogdon J, Cohen J, et al. Annual medical spending attributable to obesity: Payer-and service-specific estimates. Health Affairs 2009;28: 822-31
4. Cawley J, Meyerhoefer C, Biener A, et al. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics 2014:1-16
5. Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes 2010;3:285-95
6. Andreyeva T, Luedicke J, Wang YC. State-level estimates of obesityattributable costs of absenteeism. J Occup Environ Med 2014;56:1120-7
7. Cawley J, Rizzo JA, Haas K. The association of diabetes with job absenteeism costs among obese and morbidly obese workers. J Occup Environ Med 2008;50:527-34
8. Forhan M, Gill SV. Obesity, functional mobility and quality of life. Best Pract Res Clin Endocrinol Metab 2013;27:129-37
9. Taylor VH, Forhan M, Vigod SN, et al. The impact of obesity on quality of life. Best Pract Res Clin Endocrinol Metab 2013;27:139-46
10. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013;309:71-82
11. World Health Organization. WHO Fact Sheet 311. Geneva: World Health Organization, 2014
12. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press, 2006
13. Pan F, Goh J, Cutter G, et al. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. Clin Therapeut 2012;34:1966-76
14. Eddy D, Cohen M-D. Description of the archimedes model, ARCHeS Simulator 2.4. San Francisco, CA: Archimedes [serial online], 2012
15. Dall TM, Zhang Y, Zhang S, et al. Weight loss and lifetime medical expenditures: a case study with TRICARE prime beneficiaries. Am J Prev Med 2011;40:338-44
16. Yang W, Dall TM, Zhang Y, et al. Simulation of quitting smoking in the military shows higher lifetime medical spending more than offset by productivity gains. Health Affairs 2012;31:2717-26
17. United Kingdom Government Office for Science. Tackling obesities: future choices. 2007. https://www.gov.uk/government/collections/tackling-obesitiesfuture-choices#project-report Accessed November 21, 2014
18. Eddy D, Hollingworth W, Caro J, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force. Value Health 2012;15:843-50
19. Law A. How to build valid and credible simulation models. Proceedings of the 2008 Winter Simulation Conference 2008; 24-33
20. Dall TM, Storm M, Semilla A, et al. Value of lifestyle intervention to prevent diabetes and sequelae. Am J Prev Med 2014;48:271-80
21. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Journal of the American College of Cardiology 2014;63:2985-3023
22. NCHS (National Center for Health Statistics). Continous NHANES Web Tutorial. Hyattsville, MD, 2014. http://www.cdc.gov/nchs/tutorials/NHANES/index-continuous.htm. Accessed April 13, 2013
23. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2013;36:S67-S74
24. Adams K, Leitzmann M, Albanes D, et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol 2008;168: 268-77
25. Birmann BM, Giovannucci E, Rosner B, et al. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2007;16:1474-8
26. Chen Y, Liu L, Wang X. Body Mass Index and risk of gastric cancer: a metaanalysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomarkers Prev 2013;22:1395-408
27. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5
28. Genkinger JM, Spiegelman D, Anderson KE, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 2011;129:1708-17
29. Green LE, Dinh TA, Smith RA. An estrogen model: the relationship between body mass index, menopausal status, estrogen replacement therapy, and breast cancer risk. Comput Math Meth Med 2012;2012:Article ID 792375 (8 pages)
30. Larsson SC, Wolk A. Obesity and the risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007;97:1005-8
31. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a metaanalysis. Br J Cancer 2007;96:1457-61
32. Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer 2008;122:1418-21
33. Leitzmann MF, Brenner A, Moore SC, et al. Prospective study of body mass index, physical activity and thyroid cancer. Int J Cancer 2010;126: 2947-56
34. Lim U, Morton LM, Subar AF, et al. Alcohol, smoking, and body size in relation to incident Hodgkin's and non-Hodgkin's lymphoma risk. Am J Epidemiol 2007;166:697-708
35. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 2007;16:2533-47
36. Nagle CM, Marquart L, Bain CJ, et al. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer 2013;49:2717-26
37. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134
38. Wright ME, Chang S, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007;109:675-84
39. National Cancer Institute. Surveillance, epidemiology, and end results program. Bethesda, MD, 2011. http://seer.cancer.gov/. Accessed October 9, 2014
40. Onyike C, Crum R, Lee H, et al. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2003;158:1139-47
41. Nouwen A, Winkley K, Twisk J, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia: The European Depression in Diabetes (EDID) Research Consortium, 2010;53:2480-6
42. Eaton W, Anthony J, Gallo J, et al. Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow-up. Arch Gen Psychiatry 1997;54:993-9
43. Viner S, Szalai J, Hoffstein V. Are history and physical examination a good screening test for sleep apnea. Ann Intern Med 2011;115:356-9
44. Philips B, Cook Y, Schmitt F, Berry D. Sleep apnea: prevalence of risk factors in a general population. South Med J 1989;82:1090-2
45. Newman A, Foster A, Givelber R, et al. Progression and regression of sleepdisordered breathing with changes in weight: the Sleep Heart Health Study. Arch Intern Med 2005;165:2408-13
46. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161:1581-6
47. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003;290:66-72
48. Ruigomez A, Garcia Rodriguez LA, Wallander M, et al. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Therapeut 2004;20:751-60
49. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993;329:1912-17
50. Younossi ZM, Zheng L, Stepanova M, et al. Trends in outpatient resource utilizations and outcomes for medicare beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol 2014;49:222-7
51. Kotlarz H, Gunnarsson CL, Fang H, et al. Insurer and out-of-pocket costs of osteoarthritis in the US: Evidence from national survey data. Arthritis Rheum 2009;60:3546-53
52. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88
53. Kornum JB, Nørgaard M, Dethlefsen C, et al. Obesity and risk of subsequent hospitalization with pneumonia. Eur Respir J 2010;6:1330-6
54. Park B, Messina L, Dargon P, et al. Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the Nationwide Inpatient Sample. CHEST J 2009;136:983-90
55. Sheehan TJ, DuBrava S, DeChello LM, et al. Rates of weight change for black and white Americans over a twenty year period. Int J Obes Relat Metab Disord 2003;27:498-504
56. National Kidney and Urologic Diseases Information Clearinghouse. Kidney Disease Statistics for the United States. Bethesda, MD: National Institutes of Health [serial online], 2015
57. Centers for Disease Control and Prevention. Prevalence of coronary heart disease-United States, 2006-2010. Morb Mort Wkly Rep [serial online] 2015;60:1377
58. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics -2012 Update a report from the American Heart Association. Circulation 2012;125:e2-e220
59. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010;304:649-56
60. National Institute of Diabetes and Digestive and Kidney Diseases. 2014 Annual Data Report: epidemiology of kidney disease in the United States, Volume 2. Bethesda, MD: National Institutes of Health [serial online], 2014
61. Schaufelberger M, Swedberg K, Koster M, et al. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 2004; 25:300-7
62. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics 2013 update: a report from the American Heart Association. Circulation 2013;127:143-52
63. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, Bethesda, MD: National Cancer Institute. http://seer. cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013
64. Centers for Disease Control and Prevention NCHS. Underlying cause of death 1999-2010 on CDC WONDER online database, released 2012. Centers for Disease Control and Prevention, Hyattsville, MD: National Center for Health Statistics [serial online], 2013. http://wonder.cdc.gov/ucd-icd10.html. Accessed July 1, 2013
65. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
66. Noyes K, Dick A, Holloway R, Parkinson Study Group. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness. Pharmacoeconomics 2005;23:1257-70
67. Kulasingam S, Myers E, Lawson H, et al. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol 2006;107:321-8
68. Stein J, Newman-Casey P, Mrinalini T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2013;111:56-69
69. Phippen N, Leath C, Havrilesky L, et al. Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? Gynecol Oncol 2015;136:43-7
70. Clermont G, Kong L, Weissfeld L, et al. The effect of pulmonary artery catheter use on costs and long-term outcomes of acute lung injury. PLoS One 2011;6:e22512
71. Olden A, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med 2010;13:59-65
72. Ross E, Weinstein M, Schackman B, et al. The clinical role and cost effectiveness of long-acting antiretroviral therapy. Clin Infect Dis 2015:1102-10
73. Lee S, Anglade M, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110:845-51
74. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold. N Engl J Med 2014;371:796-7
75. Thorpe K, Florence C, Howard D, et al. The impact of obesity on rising medical spending. Health Affairs 2004;23:480-6
76. National Institude of Health. Aim for a healthy weight: key recommendations. Bethesda, MD, 2014. http://www.nhlbi.nih.gov/health/educational/lose-wt/recommen.htm. Accessed December 13, 2014
77. Nylen ES, Faselis C, Kheirbek R, et al. Statins modulate the mortality risk associated with obesity and cardiorespiratory fitness in diabetics. J Clin Endocrinol Metab 2013;98:3394-401
78. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170:1566-75
79. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-54
80. American Academy of Sleep Medicine. The International Classification of Sleep Disorders, 2nd edn. Westchester, IL: Diagnostic and Coding Manual, 2005